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The use of biomarkers is profoundly transforming medical research and practice. Their
adoption has triggered major advancements in the field of Alzheimer’s disease (AD)
over the past years. For instance, the analysis of the cerebrospinal fluid (CSF) and
neuroimaging changes indicative of neuronal loss and amyloid deposition has led to
the understanding that AD is characterized by a long preclinical phase. It is also
supporting the transition towards a biology-grounded framework and definition of the
disease. Nevertheless, though sufficient evidence exists about the analytical validity
(i.e., accuracy, reliability, and reproducibility) of the candidate AD biomarkers, their clinical
validity (i.e., how well the test measures the clinical features, and the disease or treatment
outcomes) and clinical utility (i.e., if and how the test improves the patient’s outcomes,
confirms/changes the diagnosis, identifies at-risk individuals, influences therapeutic
choices) have not been fully proven. In the present review, some of the methodological
issues and challenges that should be addressed in order to better appreciate the
potential benefits and limitations of AD biomarkers are discussed. The ultimate goal is to
stimulate a constructive discussion aimed at filling the existing gaps and more precisely
defining the directions of future research. Specifically, four main aspects of the clinical
validation process are addressed and applied to the most relevant CSF biomarkers:
(1) the definition of reference values; (2) the identification of reference standards for the
disease of interest (i.e., AD); (3) the inclusion within the diagnostic process; and (4) the
statistical process supporting the whole framework.
Keywords: biomarkers, Alzheimer’s disease, validation, diagnostic research, epidemiology, mild
cognitive impairment
INTRODUCTION
A biomarker is defined as a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or pharmacological responses to a
therapeutic intervention (Biomarkers Definitions Working Group, 2001). The use of biomarkers
is profoundly transforming medical research and practice (the so called ‘‘biomarker revolution’’;
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Schisterman and Albert, 2012). In fact, they may: (1) support
the identification of pathophysiological processes causing or
contributing to diseases; (2) define and predict the individual’s
health trajectories and clinical outcomes; and (3) help in selecting
interventions and monitoring the response to treatments.
Thus, they play a relevant role within the promise of
precision medicine approaches where medical choices are
driven by individually targeted genetic and biological profiles
(Jameson and Longo, 2015).
Biomarkers are particularly relevant in the study of
pathological conditions affecting the central nervous system
(CNS), considering that brain tissue is not readily accessible
for diagnostic or research purposes. Specifically, their adoption
has triggered major advancements in the field of Alzheimer’s
disease (AD) over the past years. For instance, the analysis of
the cerebrospinal fluid (CSF) and neuroimaging abnormalities
indicative of neuronal loss and protein deposition has led
to the understanding that AD is characterized by a long
preclinical phase (Jack et al., 2013). This finding has been
responsible for opening new perspectives in researching
novel preventive/therapeutic strategies. It has also supported
the transition towards a biology-grounded framework and
definition of the disease (Jack et al., 2018). Furthermore, the
use of these markers, when adopted as surrogate measures
of AD in animal models, has contributed in accelerating
the development of possible disease-modifying treatments
(Cummings et al., 2018).
To date, although increasingly adopted in specialized clinical
settings (Frisoni et al., 2017), the use of biomarkers to detect
AD is still recommended only for research purposes and in
selected atypical cases (McKhann et al., 2011; Dubois et al., 2014;
Jack et al., 2018). Their adoption in the routine clinical practice
remains controversial as confirmed by different systematic
reviews and meta-analyses reaching heterogeneous results on
the topic (Noel-Storr et al., 2013; Olsson et al., 2016; Ritchie
et al., 2017). In particular, though sufficient (albeit inconclusive)
evidence exists about the analytical validity (i.e., is the test
accurate, reliable, and reproducible?) of the proposed AD
biomarkers (Hansson et al., 2018; Lewczuk et al., 2018), their
clinical validity (i.e., how well the test measures the clinical
features, and the disease or treatment outcomes) and clinical
utility (i.e., if and how the test improves the patient’s outcomes,
confirms/defines the diagnosis, identifies at-risk individuals,
influences therapeutic choices) have not yet been fully proven
(Frisoni et al., 2017; Kraus, 2018).
In the present article, we discuss some of the methodological
issues and challenges that should be addressed in order to better
assess the potential benefits and limitations of AD biomarkers.
Without the intent of underestimating what has been done over
the years in the field, the ultimate goal of the present article
is to stimulate a constructive discussion aimed at filling the
existing gaps and more precisely defining the directions of future
research. The work is structured around four main aspects to
be considered when adopting a biomarker in clinical practice:
(1) the definition of reference values; (2) the identification of
reference standards specific for the disease of interest (i.e., AD);
(3) the proper inclusion and contextualization within the
diagnostic process; and (4) the statistical process supporting the
whole framework. In particular, these points will be addressed
with regard to the most relevant CSF biomarkers.
DEFINITION OF REFERENCE VALUES
The validation of a candidate biomarker should follow two
preliminary steps: (1) the assessment of its distribution
in healthy people; and (2) the definition of the index test
reference values (e.g., those included between the 2.5th and
97.5th percentile of the distribution, or within the interval
of the mean ±1.96 standard deviations in case of symmetric
distribution). The impact of common sociodemographic
characteristics (e.g., age, sex, race/ethnicity) on the identified
normal and abnormal values should also be considered
(Sackett and Haynes, 2002; Haynes and You, 2009; Colli et al.,
2014). It should be underlined, within this framework, how
challenging (or even arbitrary) the selection of the reference
group (i.e., healthy controls) to be used to define the 95% range
of reference values might be.
To assess the methodology of the studies providing reference
intervals for possible CSF biomarkers [i.e., amyloid peptides
Aβ1–42 (Aβ42), total tau (T-tau), and 181-phospo-tau (P-tau)]
in AD, we retrieved all available literature published up to
May 2019. To this purpose, we performed a structured search
on PubMed using the following search terms: (Aβ∗ OR A-β∗
OR A-beta∗ OR abeta∗ OR AB-42 OR ∗tau) AND (CSF OR
liquor OR cerebrospinal OR cerebro-spinal) AND [(population∗
OR reference∗ OR normative∗) AND (value∗ OR limit∗)] AND
(healthy OR normal OR normality OR average OR ‘‘general
population’’). The search strategy led to the identification
of 155 abstracts. The full-texts of six selected studies were
retrieved and assessed for inclusion based on the following
predefined inclusion/exclusion criteria: being published in
English; having sample size >50 subjects; defining as explicit
aim the identification of reference intervals or limits for the
considered biomarkers. Only two studies were included based
on their pertinence with and relevance to the topic of interest
(Sjögren et al., 2001; Burkhard et al., 2004). As reported in
Table 1, the two included studies showed a high heterogeneity
in how both methods and results were reported, thus limiting
their hypothetical summarization. Both studies investigated the
CSF dosage of Aβ42 and T-tau in hospital-based samples of
subjects with a wide spectrum of age (i.e., ranging from less
than 30 years to even more than 90 years). The studies adopted
the 10th fractile (or percentile) to calculate the reference limit
for Aβ42 and the 90th fractile (or percentile) to define the
reference limit for T-tau. Important differences were observed
for what concerns the age distribution and sex composition of
the enrolled study samples. Although the inconsistencies in the
reporting of results (e.g., different stratification for age groups)
preclude the possibility of a direct comparison of the findings,
a relevant discrepancy in the identified reference limits was
evident in the two studies (e.g., for Aβ42: 150 ng/L vs. 500 ng/L,
respectively). Finally, none of them assessed the role of individual
characteristics (e.g., race and genetics) that could potentially
affect results and conclusions.
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TABLE 1 | Studies reporting reference limits for CSF Aβ42 and T-tau in healthy people.
Author Setting Sample size Age Sex Diagnostic criteria for
healthy individuals
Statistics Reference limits
Sjögren
et al.
(2001)
Norwegian
University
Norwegian
Hospital
231 (total)
175
(age >50 years)
61.3 ± 18
(mean
age ± SD)
21–93 (range)
177 F
54 M
No symptoms or signs of
psychiatric or neurological
disorders:
• People aged ≥60 years:
MMSE score = 28–30
• People aged <60 years:
no criteria listed
• >0.10 fractile (i.e., 10th
percentile) for Aβ42
• <0.9 fractile (i.e., 90th
percentile) for tau
Aβ42
500 ng/L (not age
dependent)
T-tau
• 300 ng/L (for age range
21–50)
• 450 ng/L (for age range
51–70)
• 500 ng/L (for age
range ≥71)
Burkhard
et al.
(2004)
University
Hospital of
Geneve
105 (total)
82
(age >50 years)
69, 56–78
(median,
interquartile
range)
29–96 (range)
61 F
44 M
• Historical referral of
absence of any CNS or
PNS condition, or
psychiatric condition, or
chronic systemic illness
possibly modifying the CSF
proteins
• Face-to-face
questionnaire covering the
most common neurological
symptoms
• Intake of medication
potentially interfering with
brain functions
• Neuropathological
findings confirming the
absence of any dementia
(for 10 autopsy proven
cases)
• >10th percentile for Aβ42
• <90th percentile for tau
Aβ42
150 ng/L, 90% Confidence
Interval 90–172 ng/L (for
age >49 years)
T-tau
385 ng/L, 90% Confidence
Interval 332–451 ng/L (for
age >49 years)
DEFINING DIAGNOSTIC REFERENCE
STANDARDS FOR AD
The clinical validation of AD biomarkers is complicated by
the lack of a unique diagnostic reference (Noel-Storr et al.,
2013). Furthermore, the biological and clinical approaches to the
diagnosis of AD have some relevant limitations. Neuropathology
has traditionally been considered as the gold standard for the
evaluation and judgment of clinical manifestations (McKhann
et al., 1984). Nevertheless, its large-scale implementation is
hampered by the difficulty of obtaining samples. However, the
neuropathological characteristics of AD have a weak correlation
with its phenotypic and clinical expression. In fact, it is well
established that many individuals showing a high burden of
AD pathology do not exhibit any clinical signs of the disease,
whereas others with a limited amount of neuropathological
changes had developed overt AD in life (Wallace et al., 2019).
Beyond the absence of clear evidence supporting their causal
role, some of the biological processes resulting in the AD
neuropathological hallmarks (e.g., amyloid deposition) may
have different pathogenic implications (Espay et al., 2019).
They may, in fact, alternatively contribute to and accelerate
neurodegeneration, represent epiphenomena, or even constitute
compensatory mechanisms to molecular/cellular stress (Espay
et al., 2019). Moreover, different latent factors, such as the
individual’s frailty status, maymoderate the relationship between
AD pathology and dementia (Wallace et al., 2019). Finally, most
of dementia cases (including AD dementia) are underlined by a
mixed neuropathology (Boyle et al., 2018).
On the other hand, the adoption of clinical standards can
be itself prevented by several obstacles. Logically, the cross-
sectional validation of biomarkers against clinical criteria cannot
result in an optimal diagnostic accuracy (Noel-Storr et al., 2013).
Therefore, their use as prognostic markers, using longitudinal
reference standards such as the conversion from MCI to AD
dementia, are being increasingly considered for this purpose
(Ritchie et al., 2014). However, the marked heterogeneity of these
clinical outcomes may strongly confound their performance. For
instance, the phenomenon of MCI conversion may occur in
extremely variable times and ways, and be potentially affected
by several additional, interacting factors (Grande et al., 2014).
Moreover, it has been observed that a sizeable proportion of
subjects with MCI shows a normalization of neuropsychological
tests over time (Canevelli et al., 2016). Some subjects may follow
even more complex clinical trajectories, by, for example, first
reverting to normal cognition and subsequently progressing to
dementia (Roberts et al., 2014). Theoretically, such a potential
for multiple evolutions of MCI, shared by most of the risk
conditions (Canevelli et al., 2017), implies the need to overcome
the adoption of ‘‘classic’’ dichotomous outcomes (i.e., normal
vs. pathological) preferring endpoints including at least 3 levels
(i.e., improvement vs. stability vs. worsening). In other words,
biomarkers could potentially support the identification not only
of those subjects progressing to dementia, but also of those
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TABLE 2 | The diagnostic research questions.
Phase I: Do the test results in patients with the target disorder differ from those in normal people?
This preliminary phase is important to provide novel insights on the pathophysiological mechanisms of the disease. It can be addressed by conducting cross-sectional
studies confronting a convenience group of subjects known to have the disease and a group of people definitely known to not have it.
Phase II: Are patients with certain test results more likely to have the target disorder than patients with other test results?
The answer to this question can be derived by classic 2 × 2 contingency tables (or Error Matrices). The accuracy of the test (in terms of its results or cut-points) at
distinguishing patients with the disease from normal controls is expressed by means of sensitivity, specificity, positive and negative predictive values and likelihood
ratios
Phase III: Does the test result distinguish patients with and without the target disorder among patients in whom it is clinically reasonable to suspect
that the disease is present?
Differently from the previous phase, the accuracy of the test is here explored in a “real world” scenario of routine clinical practice, that is among subjects whose clinical
status is not already established (e.g., subjects referred from their general practitioners to specialist services for a clinical suspicion). Participants should, blindly, be
assessed with both the test and what is considered as the diagnostic reference standard (ideally a gold standard).
Phase IV: Do patients who undergo this diagnostic test have better health outcomes than similar patients who are not tested?
This question strongly deals with the clinical utility of the test and concerns the health outcomes following the diagnostic/therapeutic choices resulting from the test
findings. Ideally, such information could be obtained by the follow-up of subjects randomized to perform the test or not to perform it.
Phase V: Does the use of the diagnostic test lead to better health outcomes at acceptable costs?
This question refers to the cost-effectiveness (the so-called “value-for-money”) of the index test and can be answered by randomized controlled trials.
Adapted from Haynes and You (2009) and Sackett and Haynes (2002).
individuals showing an ‘‘inverse’’ trajectory towards normality.
In this framework, the possibility of combining different
biomarkers (or sets of biomarkers) should be considered with the
objective of detecting the risk of decline as well as the possibility
of restoration of a normal status.
THE ARCHITECTURE OF THE
DIAGNOSTIC PROCESS
The actual validity and utility of a diagnostic test (e.g., a
biomarker) can be summarized in a multistep process that
should answer some crucial diagnostic questions, included in five
iterative phases (Table 2; Sackett and Haynes, 2002; Haynes and
You, 2009).
In the AD literature, a relevant number of Phase I and
Phase II studies has indicated that the CSF levels of biomarkers
reflecting amyloid deposition (i.e., Aβ42) and neurodegeneration
(i.e., T-tau and P-tau) are significantly different between subjects
diagnosed with AD and to normal controls. In this context,
a recent meta-analysis of 231 studies enrolling a total of
15,699 patients with AD and 13,018 controls reported an estimate
of the following AD-to-control ratios: Aβ42 (average ratio
0.56, 95% CI 0.55–0.58, p < 0.0001), T-tau (2.54, 2.44–2.64,
p < 0.0001), and P-tau (1.88, 1.79–1.97, p < 0.0001; Olsson
et al., 2016). These biomarkers could also help in distinguishing
those subjects with mild cognitive impairment (MCI) that will
convert to dementia from non-converting subjects (Ritchie et al.,
2017). Specifically, according to a recent Cochrane systematic
review (Ritchie et al., 2017), the observed accuracy ranges of
CSF biomarkers in predicting the conversion from MCI to AD
dementia are:
- T-tau: sensitivity: 51%–90%; specificity: 48%–88%;
- P-tau: sensitivity: 40%–100%; specificity: 22%–86%;
- P-tau/Aβ42 ratio: sensitivity: 80%–96%; specificity: 33%–95%.
Such wide variability can be attributed to relevant discrepancies
in the adopted reference standards, in the source of recruitment
and sampling of participants, and in the index test methodology
across the retained studies. It is to be noted that most of
these results were obtained in research settings, evaluating
highly selected patients in whom the presence of the target
disease had already been ascertained under ideal/almost utopic
circumstances (e.g., by expert clinicians with the best available
equipment, adopting the same reference standard for those with
and without AD). These samples are unlikely to represent the
overall population of patients with AD under multiple socio-
demographic and clinical aspects. Therefore, it seems reasonable
to expect these same biomarkers to yield different results when
transferred from the research to the clinical setting (Dyer et al.,
2016; Frisoni et al., 2017). To date, only few studies have provided
realistic information on the validity of AD biomarkers in the
‘‘real world’’ (thus answering pragmatic Phase III questions). As
expected, a lower accuracy in the discrimination of patients with
and without AD was observed in these works (Mattsson et al.,
2009; Tariciotti et al., 2018). Moreover, to our knowledge, no
Phase IV andV evidence are available in this field of AD research.
In other words, no study has yet robustly explored how the use of
biomarkers can actually affect health outcomes (e.g., mortality,
disability, response to treatment; Frisoni et al., 2017) nor their
cost-effectiveness.
STATISTICAL APPROACHES ACROSS THE
DIAGNOSTIC RESEARCH PROCESS
According to the previously discussed phases, different statistical
approaches are required in each sequential step (Moons et al.,
2012a,b; Collins et al., 2015). Phase I is exploratory by nature and
is typically based on null hypothesis significance testing focused
on isolating variables deemed individually relevant according
to the P-value. The statistical methods for investigating Phase II
and III questions belong to the field of prediction models (both
diagnostic and prognostic) that typically focus on identifying
sets of variables that can accurately predict the outcomes of
interest. Considering the wide range of options and the differing
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TABLE 3 | Definition and interpretation of the Likelihood Ratio (LR).
LR values Change from pre-test to Results
post-test probability
>10 or <0.1 Large Conclusive
5–10 or 0.1–0.2 Moderate Moderately important
2–5 or 0.2–0.5 Small Sometimes important
1–2 or 0.5–1 Small/minimum Rarely important
1 None Not important/useless
Adapted from Jaeschke et al. (1994).
perspectives of researchers, clinicians and public health decision
makers, it is crucial to be aware about the trade-off between
model transparency (allowing for easy interpretability and
transparent scientific understanding) and model complexity
(maximizing the predictive power through very sophisticated
predictions that may often appear as an Opaque Black Box;
Bzdok and Ioannidis, 2019). To this purpose, simple univariable
classifications where Error Matrices (i.e., 2 × 2 contingency
tables that report the number of false positives, false negatives,
true positives, and true negatives) are derived by predefined
cut-off values of single biomarkers as well as long-trusted
multivariable statistical methods (e.g., Logistic and Cox
Regressionmodels) still remain themost suitable tools in the box.
Regarding the Error Matrix and its derived measures (Akobeng,
2007), the Positive Predictive Value (PPV) and the Likelihood
Ratio (LR) should always be preferred in prediction studies. In
fact, Sensitivity and Specificity are indicative of the accuracy
of a test (i.e., the biomarker), thus they are mostly useful for
comparing the performance of different ones (with the possibility
of combining two single tests in ‘‘OR’’/‘‘AND’’ modality to
enhance the overall sensitivity/specificity; Sackett et al., 1985).
The PPV and LR are, instead, informative about the single,
specific individual. The PPV measures the individual probability
to develop (or to have) the disease if the test is positive. The LR
expresses the probability that the test is positive (or negative)
in people with the disease compared to the probability that
it is positive (or negative) in healthy people. It thus allows to
simply update the pre-test probability of having the disease
(based on the individual’s characteristics and clinical history) to
the post-test probability (given the test results) according to its
direction and magnitude (Table 3; Jaeschke et al., 1994; Kent and
Hancock, 2016). Candidate CSF biomarkers for AD have so far
shown small to minimum LR values (i.e., LR+ 2.72, LR− 0.32 at
the median specificity of 72% for T-tau; LR+ 1.55, LR− 0.39 at
the median specificity of 47.5% for P-tau; Ritchie et al., 2017).
The predictive performance of a model is usually measured
using discrimination measures (such as c-index that is equal to
the area under the Receiver Operating Curve) and calibration
plots. These measures can be inflated in the data sample from
which they are derived when compared to new but comparable
data samples (overfitting). K-fold cross-validation and bootstrap
are the preferred internal validation techniques to evaluate
a potential overfitting. However, external validation is still
necessary to guarantee the generalizability of the model in the
real word setting (Phase III). Finally, the appropriate reporting,
communication and use of the resulting model are crucial.
Therefore, the output of the predictive model (in terms of
coefficient estimates, standard error and confidence intervals)
can be combined to graphic tools, such as nomograms, thus easily
allowing to obtain the final outcome probability for a new patient
based on his/her profile of predictive variables. This graphical
approach, although not widely used in the field of AD (Jang
et al., 2017), may have important practical implications in the
clinical and regulatory setting (e.g., patient’s counseling, risk
stratification, elaboration of guidelines, drug reimbursement).
Phase IV studies, while sharing inferential testing tools that
are similar to those used in Phase I, are usually framed within
an evidence-based decision-making context where the statistical
methods are derived from the domain of well-controlled
experimental study design (typically a randomized clinical trial).
Phase V studies, instead, focus on the evaluation of the most
effective or cost-effective diagnostic strategies through specific
cost-effectiveness analysis.
CONCLUSION
Overall, various methodological issues remain to be addressed in
order to perform an adequate and complete clinical validation
of candidate CSF biomarkers for AD. First, studies reporting the
distribution of biomarkers in normal/healthy subjects and their
variability according to major sociodemographic and clinical
attributes are still lacking. In this regard, significant sex and
race disparities for Aβ42 and tau levels have recently been
reported both in healthy subjects and in patients with AD (Koran
et al., 2017; Morris et al., 2019). Second, there is no conclusive
agreement on the most appropriate reference standard for AD
(e.g., clinical vs. biological) to be adopted to test the performance
of new biomarkers. Third, no biomarker has yet consistently
gone through all the phases that compose the architecture of
diagnostic research. In particular, their actual impact on ‘‘hard’’
health outcomes and their cost-effectiveness has to be clarified.
Similar conclusions have been reached by Mattsson et al.
(2017) who have adopted an alternative model for developing
the framework concerning AD biomarkers. Their approach,
borrowed from oncology and structured around the natural
history of the disease, should be regarded as complimentary
to that adopted in the present work, essentially based on the
methodological validation of biomarkers from the lens of clinical
epidemiology. It is also crucial that, in each phase, the scientific
contributions meet the highest quality standards. To this end, the
widespread application of the checklist on reporting standards
in dementia and cognitive impairment (STARDdem; Noel-Storr
et al., 2014) can be a useful tool to improve consistency and
transparency, and the application of the QUADAS 2 checklist
(Whiting et al., 2011) can allow the identification of potential
methodological biases, thus enabling a more effective assessment
of candidate diagnostic tests. Moreover, multivariate statistical
methodologies, possibly resulting in clinically-oriented tools
such as nomograms, should be increasingly used to capture the
complexity of the disease, both from a pathophysiological and
phenotypic perspective, and to understand the actual clinical
relevance of potential new biomarkers. It should be emphasized
how these considerations, here paradigmatically referred to
CSF, can be extended to all the candidate biomarkers for
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AD, regardless of their origin and nature (e.g., plasma, serum,
urine, neuroimaging).
In conclusion, despite the enormous progress made in the
field, there is still insufficient evidence to promote the use of
candidate CSF biomarkers for AD in the routine clinical practice,
As already pointed out by previous works on this topic, leaving
the discussed methodological issues unaddressed raises the risk
to provide clinicians with tools and tests whose answers are
difficult to interpret and translate into concrete decisions. This
might ultimately result in potential harm to patients, families,
and healthcare systems.
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